Table 1.
Patient’s characteristics
| Patient’s Characteristics | no. (%) |
|---|---|
| Sex | |
| Male | 26/56 (46.4%) |
| Female | 30/56 (53.6%) |
| Race | |
| Caucasian | 56/56 (100%) |
| Stage of disease at diagnosis | |
| I/II/IIIA | 52/56 (92.9%) |
| IIIB/IV | 4/56 (7.1%) |
| Histologic Type | |
| Adenocarcinoma | 56/56 (100%) |
| Mutation present | |
| ROR1 | 16/56 (28.6%) |
| EGFR | 5/56 (8.9%) |
| KRAS | 26/56 (46.4%) |
| ALK | 1/9 (11.1%) |
| BRAF | 1/54 (1.9%) |
| HER2 | 1/55 (1.8%) |
| TTF-1 | 45/56 (80.3%) |
| ROS1 | 0/45 (0%) |
Description of the clinicopathological features and of the mutational characterization of the cohort included in this study. Patient’s characteristics subgroups are reported in bold. Abbreviations: no number.